In terms of cancer patients or survivors, this means we are reading more about potential relationships of vitamin D deficiency and aromatase inhibitor–induced musculoskeletal symptoms (AIMSS) as well as cancer and cancer mortality, impaired bone health (osteoporosis or osteomalacia), and adverse effects with administration of bisphosphonates or denosumab (Prolia, Xgeva). This evidence concerns the gene CYP19A1 and cancer.